The 2026 American Society of Hematology (ASH) Annual Meeting, held December 12-15 in New Orleans, will feature studies on treatment selection, treatment duration, and newer immunotherapies across plasma cell disorders. In multiple myeloma, daratumumab-based quadruplets are the frontline standard, and minimal residual disease (MRD) assessment is increasingly used in trials of treatment intensity and maintenance.
In relapsed or refractory disease, earlier exposure to lenalidomide and anti-CD38 antibodies has changed the populations entering later lines. Bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies add options, but infection risk, access, and sequencing are unresolved. Smoldering myeloma needs a decision on when to treat, and AL amyloidosis needs organ function rescued before damage becomes irreversible.
The ten presentations below are selected for clinical relevance, scientific rationale, and potential effect on treatment strategy. The preview covers background, design, and the questions each study addresses.
1. AQUILA: Long-Term Follow-Up of Daratumumab in High-Risk Smoldering Multiple Myeloma
Rajkumar et al. Abstract #112
December 12, 2026
High-risk smoldering multiple myeloma is an asymptomatic precursor of active myeloma with a high short-term risk of progression. Risk depends on bone marrow plasma cell burden, monoclonal protein concentration, serum free light-chain ratio, and molecular features. Active surveillance has been the main strategy, and early treatment is increasingly considered for the highest-risk patients. The phase III AQUILA trial compared fixed-duration subcutaneous daratumumab monotherapy with active monitoring, targeting the plasma cell clone before myeloma-defining organ damage appears.
The extended follow-up addresses the early-intervention debate. Overall survival, subsequent treatment requirements, and long-term safety carry the most weight when systemic therapy is offered to asymptomatic patients. AQUILA’s high-risk definition differs from the current International Myeloma Working Group 2/20/20 criteria and may include patients with different progression probabilities. Applicability across modern risk categories will affect which patients receive daratumumab and which stay under observation.
2. PERSEUS: Long-Term Outcomes and MRD-Guided Daratumumab Discontinuation
Sonneveld et al. Abstract #111
December 12, 2026
Daratumumab plus bortezomib, lenalidomide, and dexamethasone is a major frontline regimen for transplant-eligible newly diagnosed multiple myeloma. The phase III PERSEUS trial compared this quadruplet, followed by autologous stem cell transplantation, consolidation, and daratumumab-lenalidomide maintenance, with bortezomib-lenalidomide-dexamethasone and lenalidomide maintenance. Because daratumumab runs through the whole treatment course, the duration of CD38-directed therapy is open, particularly in patients with sustained MRD negativity.
The protocol allows patients to stop daratumumab after at least 24 months of maintenance if they have a complete response or better with MRD negativity sustained for at least 12 months. Lenalidomide continues, and daratumumab is reintroduced by predefined criteria. Longer follow-up will report the durability of molecular remission, survival, and the feasibility of shortening antibody exposure. Patients were not separately randomized to stop or continue daratumumab, so the data can’t show by themselves that MRD negativity should set maintenance duration.
3. MajesTEC-5: Frontline Trispecific Antibody Therapy With Ramantamig
Raab et al. Abstract #110
December 12, 2026
T-cell-redirecting antibodies are being tested earlier in multiple myeloma, including settings where quadruplets and autologous transplantation already control disease well. Ramantamig is an investigational trispecific antibody that binds CD3 on T cells and two myeloma-associated antigens, B-cell maturation antigen (BCMA) and GPRC5D. Dual-antigen recognition may broaden tumor targeting when antigen expression is heterogeneous and may limit antigen-negative resistant clones. With daratumumab and lenalidomide, the regimen combines direct plasma cell targeting with immune modulation.
Arm G of the phase II GMMG-HD10/DSMM-XX (MajesTEC-5) study gives ramantamig, daratumumab, and lenalidomide induction to transplant-eligible patients, followed by ramantamig-daratumumab maintenance without planned upfront transplantation. The study evaluates an immunotherapy-based regimen as an alternative to upfront transplantation. Safety is the main early-phase concern: cytokine release syndrome, cytopenias, infections, hypogammaglobulinemia, and GPRC5D-associated oral and taste disturbances. Long-term disease control, preservation of stem cell collection options, and tolerability will decide if broader evaluation is feasible.
4. MagnetisMM-5: Elranatamab Monotherapy in Earlier Relapsed Multiple Myeloma
Manier et al. Abstract #424
December 12, 2026
Elranatamab is a subcutaneous BCMA × CD3 bispecific antibody for relapsed or refractory multiple myeloma. The phase II MagnetisMM-3 study established its feasibility in heavily pretreated disease and introduced response-adapted reductions in dosing frequency. MagnetisMM-5 moves it to earlier relapse, where patients retain more options and the comparators are established immunomodulatory drug- and anti-CD38-based regimens.
The phase III trial evaluates elranatamab monotherapy and elranatamab plus daratumumab against daratumumab, pomalidomide, and dexamethasone in patients previously exposed to lenalidomide and a proteasome inhibitor. The ASH presentation covers the randomized monotherapy comparison, with descriptive data from the combination arm. Daratumumab exposure before first relapse is becoming common, so the study informs sequencing after contemporary frontline therapy. Extended dosing intervals and protocol-mandated infection prevention, including immunoglobulin replacement, address the practical demands of prolonged BCMA-directed T-cell engagement.
5. EXCALIBER-RRMM: Iberdomide and the Next Generation of Cereblon Modulators
Lonial et al. Abstract #114
December 12, 2026
Cereblon E3 ligase modulators are an evolution of the immunomodulatory drug class, which has anchored myeloma treatment for more than two decades. Iberdomide is an oral agent designed for more potent cereblon-mediated degradation of the transcription factors IKZF1 and IKZF3, giving direct antimyeloma activity and enhancing immune function. Immunomodulation may complement CD38-directed antibody activity, which makes the daratumumab combination a logical pairing. Earlier studies supported evaluating iberdomide combinations in patients previously exposed to lenalidomide and other standard agents.
EXCALIBER-RRMM is a randomized phase III trial comparing iberdomide, daratumumab, and dexamethasone with daratumumab, bortezomib, and dexamethasone after one or two prior lines. It has two primary endpoints, MRD-negative complete response and progression-free survival, and the ASH presentation includes the planned progression-free survival assessment, which allows the link between molecular remission and longer-term disease control to be examined. Patients refractory to anti-CD38 antibodies or bortezomib were excluded, a notable limit given widespread frontline daratumumab use. Hematologic toxicity, infection risk, and the bortezomib-based comparator will shape interpretation.
6. MonumenTAL-6: Dual Bispecific Antibody Therapy in Relapsed Myeloma
Rodríguez-Otero et al. Abstract #426
December 12, 2026
Sequential exposure to single-antigen immunotherapies may select tumor populations with altered antigen expression. The phase I RedirecTT-1 study showed that teclistamab (BCMA × CD3) and talquetamab (GPRC5D × CD3) can be combined. Engaging two myeloma antigens addresses clonal heterogeneity and adds the potential for cumulative immune toxicity.
The randomized phase III MonumenTAL-6 trial compares teclistamab plus talquetamab and talquetamab plus pomalidomide with investigator-selected elotuzumab-pomalidomide-dexamethasone or pomalidomide-bortezomib-dexamethasone. Eligible patients have received one to four prior lines, including lenalidomide and an anti-CD38 antibody. The experimental arms test dual-antigen T-cell redirection and GPRC5D targeting supported by an immunomodulatory drug. Treatment duration, infection risk, hypogammaglobulinemia, dysgeusia, nutritional complications, and the choice of comparator all bear on use at earlier relapse.
7. BENEFIT: Long-Term Outcomes of Isatuximab-VRd in Transplant-Ineligible Multiple Myeloma
Leleu et al. Abstract #109
December 12, 2026
The phase III BENEFIT trial compared isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) with isatuximab, lenalidomide, and dexamethasone (Isa-Rd) in transplant-ineligible newly diagnosed patients with multiple myeloma, aged 65-79 years. Earlier analyses focused on MRD negativity, which gave the rationale for following progression-free survival.
The ASH 2026 analysis reports progression-free survival after approximately four years of follow-up, including outcomes in high-risk myeloma. The central comparison is the long-term benefit of adding bortezomib against its additional toxicity, particularly peripheral neuropathy, in patients with variable fitness and comorbidities. The relationship between MRD negativity and survival remains important, as does identifying patients most likely to benefit from intensification. The analysis also includes long-term survival projections, which depend on statistical assumptions and the maturity of follow-up.
8. CARTITUDE-4: Long-Term Outcomes of Cilta-cel in Daratumumab-Refractory Multiple Myeloma
Yee et al. Abstract #276
December 12, 2026
Ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T therapy, offers a mechanism with the potential for prolonged disease control after a single infusion. The phase III CARTITUDE-4 trial showed benefit of cilta-cel over standard regimens in lenalidomide-refractory myeloma after one to three prior lines. Long-term activity in patients already refractory to daratumumab is the open point.
The ASH 2026 analysis reports progression-free and overall survival by prior daratumumab exposure and refractory status among patients who received cilta-cel. The main question is treatment-free remission in patients resistant to both lenalidomide and daratumumab. The small daratumumab-refractory subgroup and the restriction to infused patients limit interpretation, but the findings could inform CAR-T sequencing after frontline anti-CD38 therapy.
9. NEXICART-2: BCMA CAR-T Therapy for Relapsed/Refractory AL Amyloidosis
Landau et al. Abstract #826
December 14, 2026
AL amyloidosis arises when a plasma cell clone produces misfolded immunoglobulin light chains that deposit in tissues and cause progressive organ dysfunction. The clone is often smaller than in symptomatic multiple myeloma, yet modest light-chain production can cause severe cardiac, renal, or neurological damage. Plasma cell-directed therapy suppresses the source of amyloidogenic light chains, but relapse is hard to treat because cumulative organ damage limits tolerance. BCMA-directed CAR-T therapy could achieve sustained clonal suppression after one infusion.
NEXICART-2 is a multicenter phase I/II study of NXC-201, an autologous BCMA-directed CAR-T product with an optimized construct designed to limit off-target activation. It enrolls patients with relapsed or refractory AL amyloidosis previously treated with a proteasome inhibitor and an anti-CD38 antibody. The primary endpoint is complete hematologic response, with cardiac and renal responses assessed separately. Organ improvement can lag well behind hematologic remission, so the interval between light-chain suppression and organ recovery is a key measurement. Cardiac status at enrollment, tolerability of lymphodepletion, and cytokine release syndrome risk will set applicability, particularly in patients with advanced organ dysfunction.
10. Frontline Teclistamab: Treating Mayo Stage IIIB AL Amyloidosis
Guan et al. Abstract #259
December 12, 2026
Advanced cardiac involvement is among the greatest challenges in AL amyloidosis. Patients with Mayo stage IIIB disease have severe cardiac dysfunction and substantial early mortality, even when treatment suppresses the plasma cell clone. The phase III ANDROMEDA trial established daratumumab-based therapy as a frontline approach but excluded stage IIIB patients, leaving the highest-risk population without trial evidence. Severe heart failure, hemodynamic instability, and limited tolerance of multidrug regimens complicate treatment.
A multicenter phase II study evaluates teclistamab monotherapy as initial treatment for newly diagnosed Mayo stage IIIB AL amyloidosis. Teclistamab redirects T cells to BCMA-expressing plasma cells and could suppress the light-chain-producing clone rapidly. The study uses step-up dosing followed by six treatment cycles, with stringent free light-chain response at one month as the primary endpoint. Urgent hematologic control has to be balanced against cytokine release syndrome, infection, and cardiac decompensation in a vulnerable population. Early survival, feasibility, and cardiac response will show if the strategy suits a group historically underrepresented in prospective trials.





